ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,306.04
0.02%
Dow Jones
38,852.86
-0.55%
US Dollar vs MXN
16.76098
-0.21%
Brent Oil
84.635
0.37%
Bitcoin
67,695.03
-0.87%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. IceCure Medical Ltd (ICCM)

  7. IceCure Medical Ltd (ICCM) Noticias

ICCM

IceCure Medical (ICCM)

IceCure Medical Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ICCM
FechaHoraFuenteTítuloSímboloCompañía
28/05/202407:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
28/05/202407:30PR Newswire (US)IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024NASDAQ:ICCMIceCure Medical Ltd
28/05/202406:31IH Market NewsU.S. Futures Present Mixed Pre-Market Performance, Oil Prices SurgeNASDAQ:ICCMIceCure Medical Ltd
21/05/202407:30PR Newswire (US)IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024NASDAQ:ICCMIceCure Medical Ltd
20/05/202407:30PR Newswire (US)IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company ShowcaseNASDAQ:ICCMIceCure Medical Ltd
07/05/202407:30PR Newswire (US)Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published GloballyNASDAQ:ICCMIceCure Medical Ltd
15/04/202407:35PR Newswire (US)IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerNASDAQ:ICCMIceCure Medical Ltd
03/04/202407:30PR Newswire (US)IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing ClearanceNASDAQ:ICCMIceCure Medical Ltd
03/04/202406:11IH Market NewsU.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge HigherNASDAQ:ICCMIceCure Medical Ltd
02/04/202407:30PR Newswire (US)IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with CryoprobesNASDAQ:ICCMIceCure Medical Ltd
27/03/202407:30PR Newswire (US)IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024NASDAQ:ICCMIceCure Medical Ltd
19/03/202407:30PR Newswire (US)IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to LumpectomyNASDAQ:ICCMIceCure Medical Ltd
12/03/202407:30PR Newswire (US)IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient OutcomesNASDAQ:ICCMIceCure Medical Ltd
07/03/202407:30PR Newswire (US)IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceNASDAQ:ICCMIceCure Medical Ltd
04/03/202407:30PR Newswire (US)IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024NASDAQ:ICCMIceCure Medical Ltd
27/02/202407:00PR Newswire (US)Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions WorkshopNASDAQ:ICCMIceCure Medical Ltd
26/02/202407:00PR Newswire (US)Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast CancerNASDAQ:ICCMIceCure Medical Ltd
15/02/202407:00PR Newswire (US)IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in JapanNASDAQ:ICCMIceCure Medical Ltd
30/01/202407:00PR Newswire (US)U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast CancerNASDAQ:ICCMIceCure Medical Ltd
29/01/202407:00PR Newswire (US)IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master ClassNASDAQ:ICCMIceCure Medical Ltd
16/01/202407:00PR Newswire (US)IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of CryoablationNASDAQ:ICCMIceCure Medical Ltd
12/01/202415:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ICCMIceCure Medical Ltd
12/01/202415:05GlobeNewswire Inc.IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price RuleNASDAQ:ICCMIceCure Medical Ltd
10/01/202407:00PR Newswire (US)IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 ResultsNASDAQ:ICCMIceCure Medical Ltd
03/01/202407:00PR Newswire (US)New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell ResponseNASDAQ:ICCMIceCure Medical Ltd
13/12/202307:00PR Newswire (US)Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"NASDAQ:ICCMIceCure Medical Ltd
29/11/202307:00PR Newswire (US)IceCure's ProSense® Deepens Regulatory Approval in IndiaNASDAQ:ICCMIceCure Medical Ltd
28/11/202307:00PR Newswire (US)IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control RateNASDAQ:ICCMIceCure Medical Ltd
15/11/202307:00PR Newswire (US)IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational HighlightsNASDAQ:ICCMIceCure Medical Ltd
15/11/202306:30PR Newswire (US)IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast CancerNASDAQ:ICCMIceCure Medical Ltd
 Showing the most relevant articles for your search:NASDAQ:ICCM

Su Consulta Reciente

NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
NYSE
BAC
Bank of America
NYSE
MCD
McDonalds
NYSE
MRK
Merck
CCOM
OILBRENT
Brent Oil
FX
EURUSD
Euro vs US Dollar
CCOM
US30
US 30
PM
XAUUSD
Gold vs US Dollar
AMEX
XLF
Financial Select Sector
NYSE
VZ
Verizon Communications
NYSE
CVX
Chevron
FX
USDMXN
US Dollar vs MXN
USOTC
ADDYY
Adidas (QX)
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados